JP7824729B2 - 神経変性疾患の予防及び／又は治療 - Google Patents

神経変性疾患の予防及び／又は治療

Info

Publication number
JP7824729B2
JP7824729B2 JP2020521460A JP2020521460A JP7824729B2 JP 7824729 B2 JP7824729 B2 JP 7824729B2 JP 2020521460 A JP2020521460 A JP 2020521460A JP 2020521460 A JP2020521460 A JP 2020521460A JP 7824729 B2 JP7824729 B2 JP 7824729B2
Authority
JP
Japan
Prior art keywords
omega
composition
acid
free
fatty
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020521460A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021505527A5 (https=
JP2021505527A (ja
Inventor
ハワード，アラン・ノーマン
ノーラン，ジョン
マルケイヒー，リオナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maravilla LLC
Original Assignee
Maravilla LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maravilla LLC filed Critical Maravilla LLC
Publication of JP2021505527A publication Critical patent/JP2021505527A/ja
Publication of JP2021505527A5 publication Critical patent/JP2021505527A5/ja
Priority to JP2025184568A priority Critical patent/JP2026016698A/ja
Application granted granted Critical
Publication of JP7824729B2 publication Critical patent/JP7824729B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2020521460A 2017-12-04 2018-05-10 神経変性疾患の予防及び／又は治療 Active JP7824729B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025184568A JP2026016698A (ja) 2017-12-04 2025-10-31 神経変性疾患の予防及び／又は治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1720119.5A GB201720119D0 (en) 2017-12-04 2017-12-04 Prevention and/or treatment of neurodegenerative disease
GB1720119.5 2017-12-04
PCT/GB2018/051255 WO2019110951A1 (en) 2017-12-04 2018-05-10 Prevention and/or treatment of neurodegenerative disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025184568A Division JP2026016698A (ja) 2017-12-04 2025-10-31 神経変性疾患の予防及び／又は治療

Publications (3)

Publication Number Publication Date
JP2021505527A JP2021505527A (ja) 2021-02-18
JP2021505527A5 JP2021505527A5 (https=) 2021-07-26
JP7824729B2 true JP7824729B2 (ja) 2026-03-05

Family

ID=60950313

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020521460A Active JP7824729B2 (ja) 2017-12-04 2018-05-10 神経変性疾患の予防及び／又は治療
JP2025184568A Pending JP2026016698A (ja) 2017-12-04 2025-10-31 神経変性疾患の予防及び／又は治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025184568A Pending JP2026016698A (ja) 2017-12-04 2025-10-31 神経変性疾患の予防及び／又は治療

Country Status (15)

Country Link
US (1) US10835509B2 (https=)
EP (2) EP3644979B1 (https=)
JP (2) JP7824729B2 (https=)
KR (1) KR20200095452A (https=)
AU (1) AU2018379644B2 (https=)
BR (1) BR112020005132A2 (https=)
CA (1) CA3071786C (https=)
ES (1) ES3047101T3 (https=)
GB (2) GB201720119D0 (https=)
IE (1) IE87241B1 (https=)
MX (1) MX2020002458A (https=)
RU (1) RU2020111305A (https=)
SG (1) SG11202000786RA (https=)
WO (1) WO2019110951A1 (https=)
ZA (1) ZA202000558B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3106957B1 (fr) * 2020-02-07 2024-05-03 Abdelhadi Zahouani Composition alimentaire pour stimuler la fonction cognitive et prevenir et limiter le declin cognitif et la demence chez des sujets adultes ou chez des sujets ages denutris
US12076299B2 (en) * 2020-02-20 2024-09-03 Arjuna Natural Pvt Ltd Composition and method to enhance cognitive support and brain health
KR20240008846A (ko) * 2021-05-17 2024-01-19 오노 야꾸힝 고교 가부시키가이샤 인지 기능을 개선하기 위한 조성물
JPWO2024143060A1 (https=) * 2022-12-26 2024-07-04

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014106741A1 (en) 2013-01-03 2014-07-10 Howard Foundation Holdings Ltd Identifying subjects in need of treatment
JP2014524914A (ja) 2011-07-07 2014-09-25 ハワード・ファウンデーション・ホールディングス・リミテッド 視覚パフォーマンス及び／若しくは黄斑色素形成の改善、又は視覚パフォーマンス及び／若しくは黄斑色素形成に関連した改善
WO2015005443A1 (ja) 2013-07-10 2015-01-15 ライオン株式会社 内服組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050163873A1 (en) 2004-01-14 2005-07-28 Robert Ritch Methods and formulations for treating glaucoma
US8324276B2 (en) * 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
WO2006116755A2 (en) * 2005-04-28 2006-11-02 Trustees Of Tufts College Synergitic effects of docosahexaenoic acid (dha) and carotenoid absorption of cognitive function
PL2219478T3 (pl) * 2007-12-17 2017-10-31 Newtricious Bv Sposób wytwarzania funkcjonalnego produktu spożywczego na bazie żółtka jaja i produkty otrzymywane tym sposobem
GB201014340D0 (en) 2010-08-27 2010-10-13 Piraee Mahmood Nutritional supplement formulation comprising saffron and resveratrol
DE212013000066U1 (de) * 2012-07-19 2014-09-25 U.S. Nutraceuticals Llc Dba Valensa International Krillöl und reagierte Astaxanthinzusammensetzung
US20140187648A1 (en) * 2013-01-03 2014-07-03 Howard Foundation Holdings Ltd. Identifying Subjects in Need of Treatment
MX2015013624A (es) * 2013-03-28 2016-06-10 Omniactive Health Technologies Ltd Efecto neuroprotector de carotenoides en el cerebro.
US20190314442A1 (en) * 2016-02-22 2019-10-17 Newtricious B.V. Composition for the prevention or treatment of neurodegenerative diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014524914A (ja) 2011-07-07 2014-09-25 ハワード・ファウンデーション・ホールディングス・リミテッド 視覚パフォーマンス及び／若しくは黄斑色素形成の改善、又は視覚パフォーマンス及び／若しくは黄斑色素形成に関連した改善
WO2014106741A1 (en) 2013-01-03 2014-07-10 Howard Foundation Holdings Ltd Identifying subjects in need of treatment
WO2015005443A1 (ja) 2013-07-10 2015-01-15 ライオン株式会社 内服組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
John M.Nolan et al.，The Impact of Supplemental Macular Carotenoids in Alzheimer's Disease: A Randomized Clinical Trial，Journal of Alzheimer's Disease，2015年02月19日，vol.44, no.4，1157-1169

Also Published As

Publication number Publication date
GB201720119D0 (en) 2018-01-17
GB2568986A (en) 2019-06-05
IE20180146A1 (en) 2019-06-12
MX2020002458A (es) 2020-07-20
CA3071786A1 (en) 2019-06-13
EP3644979A1 (en) 2020-05-06
EP4599891A3 (en) 2025-10-22
SG11202000786RA (en) 2020-06-29
AU2018379644A1 (en) 2020-03-19
NZ761512A (en) 2024-01-26
WO2019110951A1 (en) 2019-06-13
GB2568986B (en) 2019-12-18
AU2018379644B2 (en) 2024-02-08
CA3071786C (en) 2023-11-14
ES3047101T3 (en) 2025-12-03
ZA202000558B (en) 2021-10-27
RU2020111305A (ru) 2022-01-10
JP2026016698A (ja) 2026-02-03
EP4599891A2 (en) 2025-08-13
EP3644979B1 (en) 2025-08-06
US20190167624A1 (en) 2019-06-06
GB201807590D0 (en) 2018-06-27
JP2021505527A (ja) 2021-02-18
US10835509B2 (en) 2020-11-17
KR20200095452A (ko) 2020-08-10
BR112020005132A2 (pt) 2020-09-15
IE87241B1 (en) 2021-07-07

Similar Documents

Publication Publication Date Title
Welty Omega-3 fatty acids and cognitive function
Van Dael Role of n-3 long-chain polyunsaturated fatty acids in human nutrition and health: Review of recent studies and recommendations
JP2026016698A (ja) 神経変性疾患の予防及び／又は治療
Otaegui-Arrazola et al. Diet, cognition, and Alzheimer’s disease: food for thought
Rautiainen et al. Dietary supplements and disease prevention—a global overview
Mischoulon et al. Docosahexanoic acid and ω-3 fatty acids in depression
AU2011260037B2 (en) Dietary formulations
Wolf-Schnurrbusch et al. Oral lutein supplementation enhances macular pigment density and contrast sensitivity but not in combination with polyunsaturated fatty acids
US11439614B2 (en) Fish egg extracts, omega-3 lipid-based compositions and uses thereof
Demirel et al. The metabolic effects of two different lipid emulsions used in parenterally fed premature infants—a randomized comparative study
CA2599112A1 (en) Composition comprising dihomo-.gamma.-linolenic acid (dgla) as the active ingredient
Bowen et al. Carotenoids in human nutrition
US20200197349A1 (en) Cognitive function
HK40130790A (en) Prevention and/or treatment of neurodegenerative disease
US20190307715A1 (en) Prevention and/or treatment of neurodegenerative disease
US9107891B2 (en) Method for alleviating fear memory
Reddy et al. Interlinks between vitamin A and retinopathy
Ulbricht An evidence-based systematic review of lutein by the Natural Standard Research Collaboration
JP2008044894A (ja) メタボリックシンドローム改善剤
Page Macular pigment optical density during pregnancy and its relationship to the diet
Bryan The role of nutritional factors in cognitive ageing
MD Nutritional Aspects of Cognitive Impairment
HK1210388B (en) Prevention of alcohol reaction with dietary supplements
HK1210388A1 (en) Prevention of alcohol reaction with dietary supplements

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210510

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210510

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20210519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210519

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220301

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220530

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230302

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230929

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231114

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231115

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20231208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250910

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251031

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260220

R150 Certificate of patent or registration of utility model

Ref document number: 7824729

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150